During a session at the Academy of Managed Care Pharmacy’s (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, held April 23-26 in Boston, Massachusetts, Reginia Benjamin, BS, JD, director of legislative affairs for AMCP, provided an in-depth look at state legislation on biosimilars.
During a session at the Academy of Managed Care Pharmacy’s (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, held April 23-26 in Boston, Massachusetts, Reginia Benjamin, BS, JD, director of legislative affairs for AMCP, provided an in-depth look at state legislation on biosimilars.
Currently, 41 states and Puerto Rico have laws addressing biosimilars and interchangeable biosimilars, and 4 states still have bills pending, according to Benjamin. While there are 5 states that do not have biosimilar laws on the books, there is anticipation that 2 of those states will have a bill by 2019.
State legislation on biosimilars first arose in 2013, with 5 states taking the lead in developing and approving bills: Florida, North Dakota, Oregon, Utah, and Virginia. Three of the states—Utah, Oregon, and Virginia—had sunset provisions on their bills, meaning the bill would expire at the set date unless it was reenacted. All 3 bills would have expired before the first biosimilar was approved and introduced into the market, but they were reenacted by the states. By the time the first biosimilar was approved in 2015, 10 states had enacted biosimilar laws.
Benjamin then gave an overview of state legislative activity over the years. In 2013, the first biosimilar legislation required that the pharmacist notify the prescriber by either phone or fax within a specified period of time if they were going to dispense a biosimilar. There were also labeling requirements and additional record keeping that were not required for any other drug dispensed, according to Benjamin.
In 2014, new laws added provisions that notification could be achieved by adding a note into an electronic health record, so pharmacists would no longer have to phone or fax. In 2015, an entry into a pharmacy benefit manager’s system that was accessible to the prescriber was deemed as achieved notification, and in 2016, notification and labeling requirements arose for dispensing an interchangeable biosimilar. According to Benjamin, no additional provisions were added in 2017 or thus far in 2018.
Benjamin highlighted the fact that states do not use the FDA’s definition of interchangeable biosimilars. Instead, they refer to language in the Biologics Price Competition and Innovation Act (BPCIA), which references the standards of interchangeability.
State laws have also given interchangeability a 2-part definition: A biological product determined by the FDA to meet the standards of interchangeability set forth in the BPCIA, or a biological product determined by the FDA to be therapeutically equivalent as set forth by the FDA’s Orange Book—despite the fact that the Orange Book addresses small-molecule drugs and not biologics.
Additional state legislative language, which is not uniform, includes the following:
Benjamin finished up the presentation by outlining issues and challenges with current state legislation:
“It’s essential that we continue to provide patients, pharmacists, prescribers, and decision makers with educational resources to better inform them of the potential for these drugs to provide increased access to safe and more cost-effective drugs,” concluded Benjamin.
Biosimilar Policy Roundup—September 2024
October 1st 2024In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes in the industry and highlighting broader trends in market dynamics and regulatory challenges.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
French Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD
September 21st 2024An observational study assessing patient satisfaction with adalimumab for inflammatory bowel disease (IBD) reported a high level of satisfaction with all adalimumab product, including biosimilars.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).